JIP
HZNP

Jaffetilchin Investment Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Jaffetilchin Investment Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,084
Closed -$241K – 380
2023
Q3 		$241K Hold
2,084
– – 0.03% 297
2023
Q2 		$214K Sell
2,084
-56
-3% -$5.91K 0.02% 334
2023
Q1 		$234K Hold
2,140
– – 0.03% 319
2022
Q4 		$244K Buy
+2,140
New +$178K 0.03% 309
2022
Q1 		– Sell
-2,355
Closed -$254K – 397
2021
Q4 		$254K Buy
2,355
+8
+0.3% +$873 0.02% 299
2021
Q3 		$257K Hold
2,347
– – 0.03% 298
2021
Q2 		$220K Sell
2,347
-1,823
-44% -$168K 0.02% 346
2021
Q1 		$384K Buy
+4,170
New +$352K 0.05% 232

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Jaffetilchin Investment Partners's HZNP Position: Q4 2023 in Review

Jaffetilchin Investment Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,084 shares — an estimated $241K sold.

Jaffetilchin Investment Partners first reported a position in HZNP in Q1 2021 and held it in 8 quarters. The position peaked at $384K in Q1 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Jaffetilchin Investment Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 2,084 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $241K.
  • Jaffetilchin Investment Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 8 quarters.
  • Jaffetilchin Investment Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $384K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2023, filed 13 Feb 2024.